India and Brazil have signed a new MoU to enhance cooperation in pharmaceutical and medical product regulation, aiming to improve safety standards, streamline approvals, and expand access to quality healthcare products.
Glimpse:
Announced in April 2026, India’s Central Drugs Standard Control Organisation (CDSCO) and Brazil’s ANVISA signed an MoU to strengthen collaboration in regulating pharmaceuticals, biologics, and medical devices. The agreement focuses on information sharing, regulatory alignment, and improving access to safe and affordable medical products.
India and Brazil have taken a significant step toward strengthening global healthcare collaboration by signing a Memorandum of Understanding (MoU) focused on the regulation of pharmaceutical and medical products.
The agreement was signed between India’s Central Drugs Standard Control Organisation (CDSCO) and Brazil’s National Health Surveillance Agency (ANVISA), establishing a structured framework for cooperation in regulatory practices.
The MoU covers a wide range of medical products, including pharmaceutical ingredients, drugs, biological products, and medical devices, aiming to align regulatory processes and improve oversight across both countries.
A key objective of the partnership is to promote information exchange and regulatory convergence, enabling both nations to better understand each other’s systems and coordinate more effectively in monitoring product safety and quality.
The collaboration also emphasizes capacity building and knowledge sharing, allowing regulators to adopt best practices and strengthen their respective healthcare systems. This is expected to improve efficiency in approvals and enhance patient safety.
Importantly, the agreement reflects a shared commitment to ensuring the availability of safe, effective, and high-quality medicines and medical products, while also supporting affordable healthcare access for both populations.
Beyond regulatory alignment, the MoU is expected to strengthen pharmaceutical supply chains, encourage innovation, and open new avenues for trade and collaboration in the health sector.
The move builds on the broader India Brazil partnership, particularly as both countries play a key role in the Global South, working together to improve access to healthcare technologies and medicines worldwide.
Overall, the agreement marks a strategic step toward harmonized global healthcare regulation, enabling faster access to quality medical products while fostering international cooperation in the pharmaceutical and medtech sectors.
“Ensuring safe, effective and quality-assured medicines for all.”
By
HB Team
Related News
